Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Axitinib (off Label)

Axitinib vs observation (randomized Phase 2)

Pfizer · Phase 2 · Completed · Enrollment 60

NCT02859012

ArmPopulationDoseEstimandComparatorEfficacy
Axitinib 5 mg twice dailyR/M ACC with progression within 9 months (n = 60 total)5 mgITTobservationmedian progression-free survival: 10.8 months, primary analysis6-month progression-free survival: 73%, 6 monthsprogression-free survival hazard ratio vs observation: 0.25 HR, as reported in ESMO-EURACAN guidelineobjective response rate: 0%, primary analysisdisease control rate: 100%, primary analysis
ObservationR/M ACC with progression within 9 monthsnoneITTn/rmedian progression-free survival: 2.8 months, primary analysis6-month progression-free survival: 23%, 6 monthsdisease control rate: 51.9%, primary analysismedian overall survival: 27.2 months, axitinib median not reached; P 0.226